Two premarket approval records in the supplied filings name Alcon Laboratories, LLC as applicant, both under PMA number P190018 and both carrying an approval decision. The earlier record is the original Clareon approval, decided 7 January 2020; the later is supplement S050, decided 30 October 2026. The filings describe ophthalmic devices regulated under 21 CFR 886.3600 in device class 3, with the advisory committee listed as Ophthalmic. [1][2][6]

The original Clareon approval

P190018 was received 11 July 2019 and approved 7 January 2020, with a Federal Register notice date of 10 January 2020. The trade name covers the Clareon Aspheric Hydrophobic Acrylic Intraocular Lens and the Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens, and the approval statement also addresses the toric lens with the AutonoMe Pre-loaded Delivery System. The generic name is intraocular lens and the product code is HQL. [2]

The Summary of Safety and Effectiveness Data for P190018 lists model numbers for the approved devices: SY60WF for the Clareon Aspheric Hydrophobic Acrylic IOL, CNW0T3 through CNW0T9 for the Clareon Toric Aspheric Hydrophobic Acrylic IOL, and CNA0T0 for the aspheric lens with the AutonoMe Pre-loaded Delivery System. The document also names the toric lens with that delivery system. [8]

Supplement S050 and the Vivity Pro line

Supplement S050 was received 14 May 2026 and approved 30 October 2026 under the Normal 180 Day Track, with the stated supplement reason being a change in design, components, specifications or material. The expedited review flag is recorded as no. The approval statement covers Clareon Vivity Pro Extended Vision IOLs, the corresponding Toric IOLs, UV Absorbing versions of both, and configurations of each with the AutonoMe Pre-loaded Delivery System. [1]

The supplement carries product code POE and the generic name extended depth of focus intraocular lens, distinct from the HQL code on the original approval. The applicant address on the filing is in Fort Worth, Texas. The openFDA record for the same supplement repeats the applicant name and the extended depth of focus device name under regulation number 886.3600. [1][6]

What the filings establish and what they do not

The supplied collection contains two linked records, both premarket approvals, and both decisions are approvals; the record sample of two rows shows the same two approvals. These counts describe the supplied filings as of the snapshot date and are not a measure of total company portfolio, sales or safety performance. No recall records appear in the public information. [1][2]

The filings identify Alcon Laboratories, LLC as the FDA applicant for these lens devices. They do not establish a parent company, brand ownership, headquarters location, manufacturing site list or commercial availability, and the Fort Worth address is the address recorded on the filing rather than a verified headquarters. Several FDA database pages in the public information show only navigation and page furniture without device-specific content. [1][2][3][5]